India Cardiovascular Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

India Cardiovascular Devices Market Trends and Insights

Rising CVD Prevalence & Ageing Population

India’s elderly will account for 22.5% of residents by 2051, and CVDs already contribute 14.1% of national DALYs, double 1990 levels. Ischemic heart disease and stroke cases have risen 2.3-fold since 1990, creating sustained demand for stents, grafts, and rhythm devices. Urban lifestyles compound risk via hypertension and obesity, accelerating procedural volumes in the India cardiovascular devices market. The South-Asian coronary anatomy—smaller vessels and diffuse lesions—drives reliance on surgical grafting technologies. Remote monitoring platforms help manage the rising caseload by shifting routine follow-ups outside hospitals, easing congestion in tertiary centers.

Increasing Healthcare Expenditure & Insurance Penetration

Central health spending tripled to INR 3,169 per capita between 2014-2022, lifting the public share of total health outlays to 48%. Ayushman Bharat now insures 594 million citizens for up to INR 500,000, slashing out-of-pocket cardiac procedure costs by 21%. Coronary angioplasty admissions surpassed 471,000 under the scheme, directly enlarging the India cardiovascular devices market. Tier-2/3 hospitals operate at just INR 10-15 lakh per bed versus INR 1.5 crore in metros, enabling rapid cath-lab rollouts in smaller cities. Investor plans to add 17,800 private beds worth INR 14,600 crore underscore the financing momentum.

Expansion of Cath-Labs in Tier-2/3 Indian Cities

Corporate chains apply hub-and-spoke models to bring interventional cardiology closer to underserved populations, with Narayana Health scaling 7,000 beds across 51 facilities. Nearly 30% of national hospital capacity already sits in rural districts, signaling latent volume for diagnostics and consumables. Government ambulance networks and tele-ECG programs shrink response times, lifting device utilization rates outside metros. Procedure costs—heart surgery at USD 1,600 versus USD 200,000 abroad—draw regional medical tourism, enlarging local demand. Micro-insurance tie-ups widen affordability, stabilizing order pipelines for mid-priced stents and balloons.

Government PLI Scheme Boosting Local Device Manufacturing

By March 2025 the PLI scheme logged INR 1.61 lakh-crore investment and authorized 19 device factories, including CT and MRI lines, reducing 70-80% import dependence. Siemens Healthineers committed INR 91.9 crore for imaging production, while Wipro GE pledged INR 8,000 crore for device R&D and manufacturing. IIT Kanpur’s Hridayantra artificial heart and AIIMS’s domestic 1.5-tesla MRI underscore indigenous R&D progress. Import curbs on refurbished machines shelter domestic entrants, helping price-competitive valves and pacemakers reach the India cardiovascular devices market. Exports also benefit; medical-device shipments doubled to USD 4 billion in three years, signaling future scale economies.

High Cost of Advanced Implantables

The National Pharmaceutical Pricing Authority allowed stent prices to rise to INR 38,933 for drug-eluting models. Branded heart-failure drugs sell at up to 15.8 times generic rates. Customs duties on devices remain among the world’s highest at 5-7.5% and a 5% health cess. With more than 80% of critical implantables still imported, currency volatility transmits directly to end-user prices. Rural families, who shoulder travel and lodging expenses for surgery, delay care, tempering volume growth for the India cardiovascular devices market.

Limited Reimbursement Coverage

Ayushman Bharat excludes many outpatient diagnostics and next-generation therapies. Field studies in Karnataka found insured patients still incurred notable out-of-pocket costs. Smaller district hospitals struggle to meet empanelment criteria. While the September 2024 policy adds all citizens aged 70+, reimbursement ceilings remain static despite rising device prices. Delayed claim settlements discourage stocking high-ticket implants, capping the premium end of the India cardiovascular devices market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: Therapeutic Dominance Drives Volume Growth

Therapeutic and surgical systems generated 61.55% of India cardiovascular devices market size in 2025 on the back of almost half-a-million angioplasties reimbursed under Ayushman Bharat. Drug-eluting stents remain flagship items despite price ceilings, supported by anatomical complexity that demands high efficacy coatings. Pacemaker upgrades such as Abbott’s AVEIR dual-chamber leadless system target pocket-infection reduction, driving rhythm-device sales in the India cardiovascular devices market. Transcatheter valves advance quickly; Myval’s balloon-expandable platform recently enabled a TAVI-in-TAVI rescue, indicating durability.  

Diagnostic and monitoring devices will grow at 9.62% CAGR, lifting their India cardiovascular devices market share by the decade’s end. Domestic MRI and CT production can lower capital prices by 50%, unlocking installations in secondary cities. Wearable ECG patches that sync with telemedicine apps identify arrhythmias early, increasing preventative follow-up visits. Digital-twin planning relies on high-definition imaging datasets, reinforcing demand for 256-slice CT and 3-Tesla MRI as prerequisites for virtual modeling.

By Application: Coronary Leadership Faces Arrhythmia Upside

Coronary artery disease continues to anchor 42.12% of revenue, sustained by 23.8 million ischemic-heart cases and almost half-a-million annual angioplasties. Small vessel diameters and diffuse lesions encourage bypass grafting, feeding consistent pump-oxygenator and conduit demand in the India cardiovascular devices market. India attracts medical tourists with cardiac-surgery pricing 90% below developed-world tariffs, adding incremental device volume.  

Arrhythmia and conduction-disorder devices will post a 8.98% CAGR, the fastest among applications. Aging drives atrial-fibrillation incidence, while remote monitoring spots asymptomatic events, channeling patients toward ablation or pacing earlier. Personalized heart digital twins enhance ventricular-tachycardia ablation success by identifying critical substrate better than conventional voltage mapping. Structural-heart procedures gain momentum; the Tria polymer mitral valve posted zero valve-related mortality in Indian trials, signaling future diffusion.

By End User: Hospital Dominance Meets Home-Care Innovation

Hospitals and cardiac centers held 71.10% of India cardiovascular devices market share in 2025 because advanced imaging, cath-labs, and hybrid OR suites require large-scale infrastructure. Private chains have earmarked INR 14,600 crore for 17,800 new beds, while government builds additional AIIMS campuses, guaranteeing robust institutional demand. Three-dimensional mapping labs and robotic systems concentrate in tertiary units, underscoring the premium segment of the India cardiovascular devices market.  

Home-care and remote-monitoring programs will expand at 8.63% CAGR through 2031, reflecting policy focus on telehealth and the National Digital Health Mission. Wearables feed real-time data into cloud dashboards, enabling physicians to adjust therapy between visits, preventing readmissions and opening annuity-style revenue streams for vendors in the India cardiovascular devices market. Ambulatory surgical centers handle day-care angioplasties, easing hospital occupancy and spreading device consumption geographically.

Geography Analysis

Industrial clusters in Maharashtra, Karnataka, and Tamil Nadu anchor supply lines with 19 PLI-backed factories that fabricate imaging consoles, catheters, and cardiac-monitor shells, fortifying the India cardiovascular devices market against logistic shocks. Siemens Healthineers localized CT and MRI at its Bengaluru unit to cut customs delays, while Wipro GE’s multi-modality campus targets export as well as domestic demand. Southern states leverage medical-tourism inflows; cardiac packages priced at USD 1,600 attract patients from the Middle East and Africa, boosting throughput for implant and graft suppliers.

Tier-2/3 cities represent the fastest-growing geography for the India cardiovascular devices market because hospitals there can be built for one-tenth metro capex, allowing more cath-labs per million residents. Remote-robotic demonstrations, like the Gurugram-to-Jaipur heart surgery, prove specialist access can leapfrog traditional referral chains. Rajasthan, Uttar Pradesh, and Odisha recorded the steepest Ayushman Bharat cardiac-claim growth, indicating readiness for higher-end devices.

Rural districts, though the smallest slice today, hold latent potential. Government ambulance fleets and new AIIMS branches shorten referral times, while micro-insurance partnerships plug affordability gaps. Disability-adjusted life years for ischemic heart disease vary nine-fold across states, suggesting targeted outreach could unlock under-served demand for the India cardiovascular devices market. Mobile cath-lab vans and indigenous low-cost imaging expand diagnostics where brick-and-mortar builds lag, seeding future sales.

Regulatory Landscape

Cardiovascular devices in India fall under the Central Drugs Standard Control Organisation (CDSCO) and are governed through the Medical Devices Rules (MDR), 2017. The framework uses a risk-based classification approach (Class A to D), and CDSCO licensing is handled via its online portal for most products. Pricing oversight also shapes market access for key implantables, with the National Pharmaceutical Pricing Authority (NPPA) maintaining price ceilings for coronary stents.

Recent committee activity points to tighter evidence expectations and lifecycle compliance for higher-risk devices. The CDSCO Cardiovascular SEC met on March 5, 2026 to review clinical study protocols and marketing applications, while the May 21, 2025 SEC minutes included conditional recommendations linked to multi-year post-marketing clinical follow-up for a mitral valve product. In parallel, CDSCO circulated a draft update (April 1, 2025) to revise the risk-based classification list for hundreds of cardiovascular devices to align with IMDRF principles, which raises the compliance bar for quality systems and clinical documentation for manufacturers and importers.

Value Chain Analysis

The value chain runs from raw materials and precision components (including polymers, stainless steel, and specialty alloys used in stents, catheters, and valve frames) through device design and validation. Regulated manufacturing follows, typically involving ISO-aligned quality systems and CDSCO licensing, before clinical evidence generation is reviewed through CDSCO and SEC pathways.

Imports remain a major input for advanced implantables and critical sub-components, which then move through authorized importers, national distributors, and hospital procurement channels. In these hospital pathways, bundled service, training, and consumables increasingly influence vendor selection. Domestic capacity is expanding upstream and midstream, supported by government manufacturing incentives referenced in the report, including PLI-led investments and new plants targeting higher-end modalities and cardiovascular consumables. Medical device parks and clusters also strengthen downstream logistics and assembly, while SEC-related regulatory touchpoints remain central to commercialization timing for valves, catheters, and other cardiovascular technologies in cath labs and surgical programs.

Market Opportunities and Future Outlook

Structural heart, electrophysiology, and perfusion technologies represent a clear focus area as India works to move from import dependence toward localized capability. In 2026, CDSCO granted a manufacturing license to Innvolution Healthcare for producing cardiac catheterisation laboratory systems at AMTZ, which signals local build-out beyond consumables into capital equipment used to expand interventional capacity.

Component localization is also increasing, with additional capability coming online at Hyderabad's 26,000 sq ft Nitinol Wire Center of Excellence (May 2026) to support minimally invasive cardiovascular devices that rely on nitinol-based performance. The opportunity set also includes newer therapy adoption and affordability pathways that depend on regulatory clearances and domestic manufacturing licenses. Mediyant Technologies reported USFDA 510(k) clearance along with a CDSCO Class C manufacturing license for an indigenously manufactured heart-lung machine (July 2026), supporting cardiac surgery programs and local sourcing for high-value perfusion systems. On the clinical side, launches such as pulsed field ablation for atrial fibrillation (introduced in India by Medtronic in 2026) reinforce demand pull for mapping, ablation catheters, and monitoring, particularly as tier-2/3 cath lab expansion and telehealth-linked follow-up programs widen the treated patient base.